Global Proteomics Partnering Terms and Agreements Analysis Report 2020
News provided by
Share this article
Share this article
ResearchAndMarkets.com s offering.
The Global Proteomics Partnering Terms and Agreements 2010 to 2020 report provides an understanding and access to the Proteomics partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter Proteomics partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors Proteomics technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
E-Mail
WASHINGTON, DC - Investigators leading the Lung Cancer Master Protocol, or Lung-MAP trial, will present findings from three translational medicine studies at the 2020 World Conference on Lung Cancer, to be held online January 28-31, 2021.
The presentations will mark the first time that investigators share translational medicine insights from Lung-MAP, the first large-scale precision medicine trial in lung cancer backed by the National Cancer Institute (NCI), part of the National Institutes of Health, and the first major NCI trial to test multiple treatments, simultaneously, under one umbrella design. Since it launched in June 2014, the trial has tested 12 new lung cancer drugs. Lung-MAP has also amassed a scientifically valuable cache of data and biospecimens from 3,021 patients.
Share this article
Share this article
CARY, N.C., Jan. 27, 2021 /PRNewswire/ After more than two decades of dedication to advance the prevention, diagnosis, and treatment of cancer, Dr. Martin J. Murphy has retired from the Board of Directors of the CEO Roundtable on Cancer. The Board immediately elected him Director Emeritus.
Dr. Murphy was instrumental in launching the CEO Roundtable on Cancer in 2001 at the request of President George H.W. Bush who challenged him to engage action-oriented chief executives to do something more about cancer prevention, diagnosis, and treatment within your own family as well as within your corporate family.
What if we captured the spirit and urgency of Covid-19 research to cure cancer?
Covid-19 stands as a litmus test for pushing the boundaries of standardized research processes. Let’s use this shared focus, urgency, and the new partnerships being forged, to invigorate and accelerate cancer research.
Shares1
In recent months, scientists and policymakers around the globe have rallied together with one common goal: to eliminate Covid-19. Budgets have been revised to funnel money toward research, competitive barriers between scientists and companies have been lowered, and regulatory processes have been reworked to help safe and effective drugs and vaccines get to patients faster. It’s a time of urgency, of disruptive healthcare changes, and of creative problem-solving.